vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and Mastech Digital, Inc. (MHH). Click either name above to swap in a different company.

Mastech Digital, Inc. is the larger business by last-quarter revenue ($45.5M vs $33.4M, roughly 1.4× Ginkgo Bioworks Holdings, Inc.). On growth, Mastech Digital, Inc. posted the faster year-over-year revenue change (-10.4% vs -23.8%). Mastech Digital, Inc. produced more free cash flow last quarter ($4.3M vs $-47.7M). Over the past eight quarters, Mastech Digital, Inc.'s revenue compounded faster (-1.5% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.

DNA vs MHH — Head-to-Head

Bigger by revenue
MHH
MHH
1.4× larger
MHH
$45.5M
$33.4M
DNA
Growing faster (revenue YoY)
MHH
MHH
+13.4% gap
MHH
-10.4%
-23.8%
DNA
More free cash flow
MHH
MHH
$52.0M more FCF
MHH
$4.3M
$-47.7M
DNA
Faster 2-yr revenue CAGR
MHH
MHH
Annualised
MHH
-1.5%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
MHH
MHH
Revenue
$33.4M
$45.5M
Net Profit
$972.0K
Gross Margin
28.3%
Operating Margin
-211.9%
2.2%
Net Margin
2.1%
Revenue YoY
-23.8%
-10.4%
Net Profit YoY
227.3%
EPS (diluted)
$-1.41
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
MHH
MHH
Q4 25
$33.4M
$45.5M
Q3 25
$38.8M
$48.5M
Q2 25
$49.6M
$49.1M
Q1 25
$48.3M
$48.3M
Q4 24
$43.8M
$50.7M
Q3 24
$89.0M
$51.8M
Q2 24
$56.2M
$49.5M
Q1 24
$37.9M
$46.8M
Net Profit
DNA
DNA
MHH
MHH
Q4 25
$972.0K
Q3 25
$-80.8M
$941.0K
Q2 25
$-60.3M
$135.0K
Q1 25
$-91.0M
$-1.4M
Q4 24
$297.0K
Q3 24
$-56.4M
$1.9M
Q2 24
$-217.2M
$1.4M
Q1 24
$-165.9M
$-161.0K
Gross Margin
DNA
DNA
MHH
MHH
Q4 25
28.3%
Q3 25
27.8%
Q2 25
28.1%
Q1 25
26.7%
Q4 24
29.0%
Q3 24
28.5%
Q2 24
28.2%
Q1 24
25.9%
Operating Margin
DNA
DNA
MHH
MHH
Q4 25
-211.9%
2.2%
Q3 25
-231.8%
1.7%
Q2 25
-132.1%
0.1%
Q1 25
-184.1%
-3.8%
Q4 24
-236.3%
0.1%
Q3 24
-62.0%
4.7%
Q2 24
-396.7%
3.4%
Q1 24
-469.1%
-0.9%
Net Margin
DNA
DNA
MHH
MHH
Q4 25
2.1%
Q3 25
-207.9%
1.9%
Q2 25
-121.6%
0.3%
Q1 25
-188.2%
-3.0%
Q4 24
0.6%
Q3 24
-63.3%
3.6%
Q2 24
-386.4%
2.8%
Q1 24
-437.3%
-0.3%
EPS (diluted)
DNA
DNA
MHH
MHH
Q4 25
$-1.41
$0.08
Q3 25
$-1.45
$0.08
Q2 25
$-1.10
$0.01
Q1 25
$-1.68
$-0.12
Q4 24
$-1.91
$0.01
Q3 24
$-1.08
$0.16
Q2 24
$-4.23
$0.12
Q1 24
$-3.32
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
MHH
MHH
Cash + ST InvestmentsLiquidity on hand
$422.6M
$36.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$89.3M
Total Assets
$1.1B
$111.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
MHH
MHH
Q4 25
$422.6M
$36.5M
Q3 25
$495.5M
$32.7M
Q2 25
$559.4M
$27.9M
Q1 25
$325.3M
$24.7M
Q4 24
$561.6M
$27.7M
Q3 24
$616.2M
$23.9M
Q2 24
$730.4M
$20.6M
Q1 24
$840.4M
$19.4M
Stockholders' Equity
DNA
DNA
MHH
MHH
Q4 25
$508.6M
$89.3M
Q3 25
$559.8M
$88.0M
Q2 25
$613.0M
$87.8M
Q1 25
$647.4M
$86.9M
Q4 24
$716.1M
$87.4M
Q3 24
$797.9M
$86.5M
Q2 24
$833.1M
$84.0M
Q1 24
$987.3M
$81.7M
Total Assets
DNA
DNA
MHH
MHH
Q4 25
$1.1B
$111.8M
Q3 25
$1.2B
$112.6M
Q2 25
$1.2B
$110.4M
Q1 25
$1.3B
$110.1M
Q4 24
$1.4B
$111.5M
Q3 24
$1.5B
$111.5M
Q2 24
$1.6B
$107.5M
Q1 24
$1.6B
$106.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
MHH
MHH
Operating Cash FlowLast quarter
$-47.7M
$4.4M
Free Cash FlowOCF − Capex
$-47.7M
$4.3M
FCF MarginFCF / Revenue
-142.8%
9.5%
Capex IntensityCapex / Revenue
0.0%
0.1%
Cash ConversionOCF / Net Profit
4.48×
TTM Free Cash FlowTrailing 4 quarters
$10.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
MHH
MHH
Q4 25
$-47.7M
$4.4M
Q3 25
$-31.6M
$6.5M
Q2 25
$-40.3M
$3.3M
Q1 25
$-51.5M
$-3.0M
Q4 24
$-42.4M
$4.0M
Q3 24
$-103.5M
$3.3M
Q2 24
$-84.4M
$1.2M
Q1 24
$-89.3M
$-1.3M
Free Cash Flow
DNA
DNA
MHH
MHH
Q4 25
$-47.7M
$4.3M
Q3 25
$6.3M
Q2 25
$-40.3M
$3.2M
Q1 25
$-59.1M
$-3.1M
Q4 24
$-56.1M
$3.9M
Q3 24
$-118.6M
$3.2M
Q2 24
$-111.4M
$707.0K
Q1 24
$-96.0M
$-1.6M
FCF Margin
DNA
DNA
MHH
MHH
Q4 25
-142.8%
9.5%
Q3 25
13.0%
Q2 25
-81.2%
6.6%
Q1 25
-122.4%
-6.4%
Q4 24
-128.0%
7.7%
Q3 24
-133.2%
6.2%
Q2 24
-198.2%
1.4%
Q1 24
-252.9%
-3.4%
Capex Intensity
DNA
DNA
MHH
MHH
Q4 25
0.0%
0.1%
Q3 25
0.0%
0.4%
Q2 25
0.1%
0.1%
Q1 25
15.8%
0.2%
Q4 24
31.3%
0.2%
Q3 24
16.9%
0.1%
Q2 24
48.1%
1.0%
Q1 24
17.7%
0.6%
Cash Conversion
DNA
DNA
MHH
MHH
Q4 25
4.48×
Q3 25
6.88×
Q2 25
24.41×
Q1 25
Q4 24
13.60×
Q3 24
1.76×
Q2 24
0.85×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

MHH
MHH

IT Staffing Services$37.6M83%
Data And Analytics Services$7.8M17%

Related Comparisons